Skip to main content
SpringerLink
Log in

The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients

  • Communication
  • Published:
Lipids

Abstract

We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

apo:

Apolipoprotein

apoA-I:

Apolipoprotein A-I

apoB:

Apolipoprotein B

apoC-II:

Apolipoprotein C-II

apoC-III:

Apolipoprotein C-III

apoE:

Apolipoprotein E

BMI:

Body mass index

CVD:

Cardiovascular disease

Group O:

Orlistat group

Group E:

Ezetimibe group

Group OE:

Orlistat plus ezetimibe group

HDL:

High density lipoproteins

HDL-C:

High density lipoprotein cholesterol

HL:

Hepatic lipase

HOMA:

Homeostasis model assessment

LDL-C:

Low density lipoprotein cholesterol

LPL:

Lipoprotein lipase

MetS:

Metabolic syndrome

TG:

Triglycerides

TC:

Total cholesterol

VLDL:

Very low density lipoproteins

References

  1. Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484

    CAS  PubMed  Google Scholar 

  2. Wang CS (1991) Structure and functional properties of apolipoprotein C-II. Prog Lipid Res 30:253–258

    Article  CAS  PubMed  Google Scholar 

  3. Chan DC, Chen MM, Ooi EM, Watts GF (2008) An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 62:799–809

    Article  CAS  PubMed  Google Scholar 

  4. Filippatos TD, Mikhailidis DP (2009) Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 15:490–516

    Article  CAS  PubMed  Google Scholar 

  5. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O’Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 102:8132–8137

    Article  CAS  PubMed  Google Scholar 

  6. Kiortsis DN, Filippatos TD, Elisaf MS (2005) The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 31:15–22

    Article  CAS  PubMed  Google Scholar 

  7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS (2008) Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 31:53–65

    Article  CAS  PubMed  Google Scholar 

  8. Filippatos T, Derdemezis C, Elisaf M (2009) Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clin Lipidol 4:331–341

    Article  CAS  Google Scholar 

  9. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN (2007) The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193:428–437

    Article  CAS  PubMed  Google Scholar 

  10. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS (2005) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 21:1997–2006

    Article  CAS  PubMed  Google Scholar 

  11. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS (2008) The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 10:476–483

    Article  CAS  PubMed  Google Scholar 

  12. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 24:1919–1929

    Article  CAS  PubMed  Google Scholar 

  13. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, Mikhailidis DP, Elisaf MS (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 9:3151–3158

    Article  CAS  PubMed  Google Scholar 

  14. Sakurabayashi I, Saito Y, Kita T, Matsuzawa Y, Goto Y (2001) Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta 312:87–95

    Article  CAS  PubMed  Google Scholar 

  15. Ooi EM, Barrett PH, Chan DC, Watts GF (2008) Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 114:611–624

    Article  CAS  Google Scholar 

  16. Yamamoto M, Morita SY, Kumon M, Kawabe M, Nishitsuji K, Saito H, Vertut-Doi A, Nakano M, Handa T (2003) Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions. Biochim Biophys Acta 1632:31–39

    CAS  PubMed  Google Scholar 

  17. Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 75:384–390

    Article  CAS  PubMed  Google Scholar 

  18. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV (1986) Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78:1287–1295

    Article  CAS  PubMed  Google Scholar 

  19. Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM (2001) Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 42:1578–1585

    CAS  PubMed  Google Scholar 

  20. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS (1992) Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33:995–1003

    CAS  PubMed  Google Scholar 

  21. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, Mikhailidis DP, Elisaf M (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 23:1169–1176

    Article  CAS  PubMed  Google Scholar 

  22. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother 9:1829–1837

    Article  CAS  PubMed  Google Scholar 

  23. Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS (2007) A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 29:1403–1414

    Article  CAS  PubMed  Google Scholar 

  24. Bradley WA, Hwang SL, Karlin JB, Lin AH, Prasad SC, Gotto AM Jr, Gianturco SH (1984) Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem 259:14728–14735

    CAS  PubMed  Google Scholar 

  25. Brown SA, Via DP, Gotto AM Jr, Bradley WA, Gianturco SH (1986) Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting. Biochem Biophys Res Commun 139:333–340

    Article  CAS  PubMed  Google Scholar 

  26. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41:305–318

    CAS  PubMed  Google Scholar 

  27. Caslake MJ, Packard CJ (2004) Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol 15:387–392

    Article  CAS  PubMed  Google Scholar 

  28. Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, Couture P (2006) Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 26:1101–1106

    Article  CAS  PubMed  Google Scholar 

  29. Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC, Ohama T, Nishida M, Ishigami M, Yamashita S (2009) Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 39:689–698

    Article  CAS  PubMed  Google Scholar 

  30. Wang CS, Downs D, Dashti A, Jackson KW (1996) Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli. Biochim Biophys Acta 1302:224–230

    PubMed  Google Scholar 

  31. Fojo SS, Brewer HB (1992) Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 231:669–677

    Article  CAS  PubMed  Google Scholar 

  32. Jong MC, Havekes LM (2000) Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice. Int J Tissue React 22:59–66

    CAS  PubMed  Google Scholar 

  33. Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Enzi GB, Verlato F, Baiocchi MR, Sprecher DL, Kashyap ML et al (1986) Apolipoprotein C-II deficiency syndrome clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest 77:520–527

    Article  CAS  PubMed  Google Scholar 

  34. Reina M, Brunzell JD, Deeb SS (1992) Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes. J Lipid Res 33:1823–1832

    CAS  PubMed  Google Scholar 

  35. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Goldberg IJ, Ginsberg HN, Breslow JL (1994) Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 93:1683–1690

    Article  CAS  PubMed  Google Scholar 

  36. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL (1990) Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 265:10771–10779

    CAS  PubMed  Google Scholar 

  37. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC (1995) Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 15:963–971

    CAS  PubMed  Google Scholar 

  38. Lucas CP, Boldrin MN, Reaven GM (2003) Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 91:961–964

    Article  CAS  PubMed  Google Scholar 

  39. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW (1994) Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43:293–298

    Article  CAS  PubMed  Google Scholar 

  40. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS (2002) Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet Med 19:944–948

    Article  CAS  PubMed  Google Scholar 

  41. Filippatos T, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari E, Kiortsis D, Elisaf M (2008) Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2:279–284

    Article  Google Scholar 

  42. Fernandez ML, Metghalchi S, Vega-Lopez S, Conde-Knape K, Lohman TG, Cordero-Macintyre ZR (2004) Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. J Nutr Biochem 15:717–721

    Article  CAS  PubMed  Google Scholar 

  43. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P (2000) Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 43:703–708

    Article  CAS  PubMed  Google Scholar 

  44. Lee SJ, Campos H, Moye LA, Sacks FM (2003) LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 23:853–858

    Article  CAS  PubMed  Google Scholar 

  45. Gerber Y, Goldbourt U, Segev S, Harats D (2003) Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study. Prev Med 37:18–22

    Article  CAS  PubMed  Google Scholar 

  46. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P (1996) Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur ‘Infarctus du Myocarde. J Lipid Res 37:508–517

    CAS  PubMed  Google Scholar 

  47. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH (1994) Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90:42–49

    CAS  PubMed  Google Scholar 

  48. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102:1886–1892

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, School of Medicine, University of Ioannina, 45 110, Ioannina, Greece

    E. S. Nakou, T. D. Filippatos, A. P. Agouridis & M. S. Elisaf

  2. Laboratory of Clinical Chemistry, School of Medicine, University of Ioannina, Ioannina, Greece

    C. Kostara & E. T. Bairaktari

Authors
  1. E. S. Nakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. D. Filippatos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. P. Agouridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Kostara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. T. Bairaktari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. S. Elisaf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. S. Elisaf.

About this article

Cite this article

Nakou, E.S., Filippatos, T.D., Agouridis, A.P. et al. The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients. Lipids 45, 445–450 (2010). https://doi.org/10.1007/s11745-010-3409-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11745-010-3409-0

Keywords

Search

Navigation